When was JenaValve Technology founded?

JenaValve Technology was founded in 2006.

Where is JenaValve Technology located?

JenaValve Technology is located in Irvine, United States .

Who is the current CEO of JenaValve Technology?

John Kilcoyne is the current CEO of JenaValve Technology.

How many employees does JenaValve Technology have?

JenaValve Technology has 198 employees as of Dec 31, 2023.

When was the latest funding round of JenaValve Technology?

JenaValve Technology's latest funding round was on Dec 21, 2021.

Where does JenaValve Technology rank among its competitors?

JenaValve Technology ranks 2 amongst 106 active competitors.

Who are the top competitors of JenaValve Technology?

JenaValve Technology's top competitors are Shockwave Medical, Venus MedTech and Cardiac Dimensions.

JenaValve Technology - 2025 Company Profile, Funding & Competitors

JenaValve Technology is an acquired company based in Irvine (United States), founded in 2006. It operates as a Provider of pericardial transcatheter aortic valve replacement and delivery system. JenaValve Technology has raised $364M in funding from investors like Sunstone, Gimv and Valiance Asset Management. The company has 106 active competitors, including 48 funded and 29 that have exited. Its top competitors include companies like Shockwave Medical, Venus MedTech and Cardiac Dimensions.

Company Details

Provider of pericardial transcatheter aortic valve replacement and delivery system. It offers Trilogy Valve with locator technology that includes a root valve sewn onto a stent and a delivery system for the treatment of aortic valve stenosis for treatment of patients suffering from the aortic valve insufficiency.

Website
Social
Registered Address: 4 Cromwell Irvine, CA 92618

Key Metrics

Founded Year

2006

Location

Irvine, United States

Stage

Acquired

Total Funding

in 13 rounds

Latest Funding Round

Investors

Sunstone & 20 more

Ranked

2^nd among

Employee Count

as on Dec 31, 2023

Similar Companies

Shockwave Medical &

Exit Details

Acquired by Edwards Lifesciences (Jul 25, 2024)

JenaValve Technology is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CIN: 4132238 United States, Active	Mar 26, 2006	-	128 (as on Dec 31, 2023)	-
CIN: 09520509 Belgium, Active	Mar 30, 2015	-	60 (as on Dec 31, 2023)	-
CIN: HRB 167207. Germany, Active	Mar 29, 2007	-	10 (as on Dec 31, 2023)	-

Get your free copy of JenaValve Technology's company profile

JenaValve Technology got acquired by Edwards Lifesciences on Jul 25, 2024.

Click to take a look at JenaValve Technology's acquisition in detail

JenaValve Technology has raised a total funding of $364M over 13 rounds. Its first funding round was on Sep 22, 2006. Its latest funding round was a Series C round on Dec 21, 2021 for $100M. 11 investors participated in its latest round, lead by Bain Capital Life Sciences.

JenaValve Technology has 21 institutional investors including Sunstone, Gimv and Valiance Asset Management.

Here is the list of recent funding rounds of JenaValve Technology:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Dec 21, 2021	$100M	Series C	4081201	4658931	Bain Capital Life Sciences, Andera Partners, and
Jan 31, 2020	$66.5M	Series C	1811264	3991833	Andera Partners, Gimv, and
Jun 06, 2019	$14.5M	Series C	4157239	8109808	-

Access funding benchmarks and valuations. Sign up today!

View details of JenaValve Technology's funding rounds and investors

JenaValve Technology's employee count trend

JenaValve Technology has 198 employees as of Dec 23. The total employee count is 13.0% more than what it was in Dec 22. Here is JenaValve Technology's employee count trend over the years:

Employee count trend for JenaValve Technology

Uncover JenaValve Technology's growth story! Sign up today!

Access 秘密研究所 on any website

Our Google Chrome extension lets you view company details while browsing their websites

Top competitors of JenaValve Technology include Shockwave Medical, Venus MedTech and Cardiac Dimensions. Here is the list of Top 10 competitors of JenaValve Technology, ranked by 秘密研究所 score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Shockwave Medical 2009, Santa Clara (United States), Acquired	Developer of cardiovascular balloon dilation catheters	$148M	Venrock, HTIF听&补尘辫;听	63/100
2nd	2006, Irvine (United States), Acquired	Provider of pericardial transcatheter aortic valve replacement and delivery system	$364M	NeoMed, Omega Funds听&补尘辫;听	60/100
3rd	Venus MedTech 2009, Hangzhou (China), Public	Transcatheter aortic valves	$37M	DCP, Goldman Sachs Investment Partners听&补尘辫;听	60/100
4th	Cardiac Dimensions 2001, Kirkland (United States), Series E	Developer of invasive cardiac implants for heart failure	$261M	InterWest Partners, Frazier Healthcare Partners听&补尘辫;听	60/100
5th	Peijia Medical Technologies 2012, Suzhou (China), Public	Developer of medical devices for the treatment of cardiac and cerebrovascular diseases	$110M	Octagon Capital Advisors, Spinnotec听&补尘辫;听	57/100
6th	MicroPort CardioFlow Medtech Corporation 2015, Pudong (China), Public	Developer of smart medical devices for patients with heart valve diseases	$132M	Hillhouse, CPE听&补尘辫;听	56/100
7th	Pi-Cardia 2009, Rehovot (Israel), Series D	Developer of non-implant device for valve repair	$40M	Kreos Capital, Sofinnova Partners听&补尘辫;听	55/100
8th	Capstan Medical 2020, Santa Cruz (United States), Series C	Developer of medical devices for the treatment of structural heart diseases	$141M	GT Healthcare Capital Partners, Eclipse听&补尘辫;听	55/100
9th	Anteris Technologies 2011, Brisbane (Australia), Public	Provider of technologies for developing heart valve	-	Perceptive Advisors, 听&补尘辫;听	53/100
10th	TRiCares 2013, Aschheim (Germany), Series D	Developer of a minimally invasive tricuspid valve replacement system. This system is designed to treat tricuspid regurgitation, a serious heart condition, without the need for open-heart surgery. The company focuses on developing a safe and effective solution to address the limitations of existing treatment approaches. It is developing a catheter-based system for tricuspid valve replacement. The company's efforts include clinical trials and securing funding to support further development and clinical milestones.	$103M	Wellington Partners Venture Capital, Credit Mutuel Equity听&补尘辫;听	52/100